Filtros de búsqueda

Lista de obras de Alan F List

A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)

artículo científico publicado en 2016

A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia

artículo científico publicado en 2017

A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes

scientific article published on 20 December 2018

A close association of autoimmune-mediated processes and autoimmune disorders with chronic myelomonocytic leukemia: observation from a single institution

artículo científico publicado en 2014

A decade of progress in myelodysplastic syndrome with chromosome 5q deletion

artículo científico publicado en 2018

A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies.

artículo científico publicado en 2000

A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia

artículo científico publicado en 2013

A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy.

artículo científico publicado en 2015

A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605.

artículo científico publicado en 2011

A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes

artículo científico publicado en 2014

A phase I trial of 14-day continuous intravenous infusion mitoxantrone ⬇️

artículo científico publicado el 1 de junio de 1991

A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia.

artículo científico publicado en 2008

A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction. ⬇️

artículo científico publicado en 2014

A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma

artículo científico publicado en 2000

A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study Group

scientific article published on 01 February 2000

ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS.

artículo científico publicado en 2017

Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) MDS.

artículo científico publicado en 2014

Acanthocytosis associated with myelodysplasia

artículo científico publicado en 1989

Acute nonlymphocytic leukemia after treatment of small cell lung cancer

scientific article published on 01 December 1986

Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis

artículo científico publicado en 1986

Advancements in the molecular pathogenesis of myelodysplastic syndrome.

scientific article published on March 2009

Advances in the management of myelofibrosis

artículo científico publicado en 2012

Age-related inflammatory bone marrow microenvironment induces ineffective erythropoiesis mimicking del(5q) MDS.

artículo científico publicado en 2017

Alpha-interferon in the treatment of idiopathic myelofibrosis

artículo científico publicado el 1 de abril de 1992

Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome

artículo científico publicado en 2009

Alternative treatments for myelodysplastic syndromes.

artículo científico publicado en 2005

Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained

artículo científico publicado en 1997

Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity

scientific article published on 01 August 1996

Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors

artículo científico publicado en 1998

Amifostine: a tonic or toxin to myeloid progenitors

artículo científico publicado en 2000

An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.

artículo científico publicado en 2015

An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults

artículo científico publicado en 2015

An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies.

artículo científico publicado en 2015

Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells.

artículo científico publicado en 1994

Applying synthetic lethality for the selective targeting of cancer.

artículo científico publicado en 2014

Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study.

artículo científico publicado en 2018

Association of EZH2 protein expression by immunohistochemistry in myelodysplasia related neoplasms with mutation status, cytogenetics and clinical outcomes.

artículo científico publicado en 2018

Autoimmune diseases and myelodysplastic syndromes

artículo científico publicado en 2016

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

artículo científico publicado en 2009

Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation

artículo científico publicado en 2017

Biology and pathogenesis of the myelodysplastic syndromes

artículo científico publicado el 1 de febrero de 1992

Biology and treatment of the 5q- syndrome.

artículo científico publicado en 2011

Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience.

artículo científico publicado en 2016

Burkitt's lymphoma in a homosexual

artículo científico publicado en 1982

Challenges in myelodysplastic syndromes: raising awareness and promoting new insight in therapeutic options

artículo científico publicado en 2008

Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study model.

artículo científico publicado en 2013

Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure.

artículo científico publicado en 2013

Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study

artículo científico publicado en 2016

Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome.

artículo científico publicado en 2012

Comparative pharmacokinetic study of high-dose etoposide and etoposide phosphate in patients with lymphoid malignancy receiving autologous stem cell transplantation ⬇️

artículo científico publicado el 1 de abril de 2003

Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium

artículo científico publicado en 2017

Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and combined with GM-CSF or G-CSF

scientific article published on 01 February 1996

Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.

artículo científico publicado en 2015

Complete hematologic remission with oral etoposide in a patient with chronic myelomonocytic leukemia and profound dyserythropoiesis

scientific article published on 01 May 1994

Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes

artículo científico publicado en 2011

Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States

scientific article published on 01 December 2006

Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature.

scientific article published on 22 July 2011

Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase.

artículo científico publicado en 2002

Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.

artículo científico publicado en 2012

Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML).

artículo científico publicado en 1996

Cytokine targets in the treatment of myelodysplastic syndromes.

artículo científico publicado en 2005

Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis

scientific article published on 03 April 2019

Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome

artículo científico publicado en 2012

Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: relationship to HLA expression and host immunocompetence

scientific article published on 01 March 1993

Deletion 5q MDS: molecular and therapeutic implications.

artículo científico publicado en 2013

Deletions of Xp22.2 including PIG-A locus lead to paroxysmal nocturnal hemoglobinuria

artículo científico publicado en 2010

Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes

scientific article published on 01 January 2011

Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes

artículo científico publicado en 2014

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

artículo científico publicado en 1997

Donor-derived constitutional chromosomal abnormalities after allogeneic hematopoietic cell transplantation: a single-center experience and a review of the literature.

artículo científico publicado en 2015

Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide.

artículo científico publicado en 2009

ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia

artículo científico publicado en 2014

Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion.

artículo científico publicado en 2012

Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale.

artículo científico publicado en 2016

Emerging immunosuppressive drugs in myelodysplastic syndromes.

artículo científico publicado en 2012

Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.

artículo científico publicado en 2008

Erythropoietin Receptor Signaling and Lipid Rafts.

artículo científico publicado en 2017

Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky Memorial lecture.

artículo científico publicado en 2003

Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome

artículo científico publicado en 2017

Evolving applications of lenalidomide in the management of anemia in myelodysplastic syndromes.

artículo científico publicado en 2006

Evolving trends in the treatment of low-risk myelodysplastic syndromes: immunomodulation and beyond--9th European Hematology Association Congress Geneva, Switzerland, 10-13 June 2004

artículo científico publicado en 2007

Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome.

artículo científico publicado en 2012

Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype ⬇️

artículo científico publicado el 1 de mayo de 1991

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

artículo científico publicado en 2015

Extratesticular lesions: a radiological and pathological correlation

artículo científico publicado en 1994

First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.

artículo científico publicado en 2011

Fulminant Kaposi's sarcoma complicating long-term corticosteroid therapy.

artículo científico publicado en 1987

Functional hyposplenism

artículo científico publicado en 1987

GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia.

artículo científico publicado en 2013

Gastrostomy-biliary drainage in a patient with bile duct cancer: a basis for multimodality treatment

artículo científico publicado en 1989

Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity.

artículo científico publicado en 2005

Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients

artículo científico publicado en 2018

Granulocytic sarcoma in myelodysplastic syndromes: clinical marker of disease acceleration

artículo científico publicado en 1991

Hematopoietic progenitor cell content of bone marrow harvests: relative contributions of blood and bone marrow

artículo científico publicado en 1994

Hematopoietic stimulation by amifostine and sodium phenylbutyrate: what is the potential in MDS?

artículo científico publicado en 1998

Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML

scientific article published on 19 July 2018

High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainment.

artículo científico publicado en 2013

Hyperleukocytosis complicating lonafarnib treatment in patients with chronic myelomonocytic leukemia.

artículo científico publicado en 2005

Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening

artículo científico publicado en 2009

Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes

artículo científico publicado en 2011

Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia.

artículo científico publicado en 2016

Immunomodulation in myelodysplastic syndromes.

artículo científico publicado en 2006

Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia.

artículo científico publicado en 2009

Immunomodulatory drugs.

artículo científico publicado en 2005

Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome

artículo científico publicado en 2016

Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report

artículo científico publicado en 2017

Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.

artículo científico publicado en 2015

Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine

artículo científico publicado en 2017

Impact of tobacco usage on disease outcome in myelodysplastic syndromes.

artículo científico publicado en 2015

Improved intra-array and interarray normalization of peptide microarray phosphorylation for phosphorylome and kinome profiling by rational selection of relevant spots

artículo científico publicado en 2016

Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries.

artículo científico publicado en 2011

Induction of myelodysplasia by myeloid-derived suppressor cells.

artículo científico publicado en 2013

Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity

artículo científico publicado en 2018

Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.

artículo científico publicado en 2006

Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS.

artículo científico publicado en 2008

Intrapatient functional clonality deconvoluted by coupling intracellular flow cytometry and next-generation sequencing in human leukemia

artículo científico publicado en 2017

Introduction: myeloproliferative disorders

artículo científico publicado en 1995

JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth

artículo científico publicado en 2012

KG-1 and KG-1a model the p15 CpG island methylation observed in acute myeloid leukemia patients.

artículo científico publicado en 2001

Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: Is it any good?

scientific article published on 01 March 2006

Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: is it any good?

artículo científico publicado en 2005

Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41.

artículo científico publicado en 2016

Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine.

artículo científico publicado en 2015

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.

artículo científico publicado en 2012

Lenalidomide for treatment of myelodysplastic syndromes.

artículo científico

Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions.

scientific article published on April 2010

Lenalidomide in myelodysplastic syndromes.

artículo científico publicado en 2008

Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors

artículo científico publicado en 2014

Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.

artículo científico publicado en 2009

Lenalidomide--the phoenix rises.

artículo científico publicado en 2007

Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.

artículo científico publicado en 2017

Lenalidomide: from bench to bedside (part 1)

scientific article published on 01 December 2006

Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.

artículo científico publicado en 2006

Limited erythropoietic response to combined treatment with recombinant human interleukin 3 and erythropoietin in myelodysplastic syndrome

artículo científico publicado en 1999

Loss of Function of DOCK4 in Myelodysplastic Syndromes Stem Cells is Restored by Inhibitors of DOCK4 Signaling Networks

scientific article published on 15 July 2019

Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis

artículo científico publicado en 2012

Low itraconazole serum concentrations following administration of itraconazole suspension to critically ill allogeneic bone marrow transplant recipients

artículo científico publicado en 1995

Lung cancer after exposure to radon daughters

scientific article published on 01 September 1984

Lung cancer in Hodgkin's disease: association with previous radiotherapy

artículo científico publicado en 1985

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

scientific article published on 01 January 2020

Malignant hypercalcemia. The choice of therapy

artículo científico publicado en 1991

Management of RBC-transfusion dependence.

artículo científico publicado en 2007

Management of lower-risk myelodysplastic syndromes: the art and evidence.

artículo científico publicado en 2011

Mast cell growth factor (c-kit ligand) restores growth of multipotent progenitors in myelodysplastic syndrome

artículo científico publicado en 1994

Metastatic giant-cell bone tumor in a man positive for HIV

scientific article published on 01 February 1988

Methyltransferase inhibitors: changing the treatment algorithm for myelodysplastic syndromes.

artículo científico publicado en 2004

Molecular pathogenesis of myelodysplastic syndromes with deletion 5q

scientific article published on 16 January 2019

Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide.

artículo científico publicado en 2016

Monoclonal gammopathy of undetermined significance disguised as chronic neutrophilic leukemia.

artículo científico publicado en 2010

Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis

artículo científico publicado en 2017

Multidrug resistance in acute leukemia: a conserved physiologic function

artículo científico publicado el 1 de septiembre de 1992

Multikinase inhibitors for treating high-risk myelodysplastic syndromes: can this be brought into clinical practice?

artículo científico publicado en 2013

Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies.

artículo científico publicado en 2013

Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia.

artículo científico publicado en 2016

Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.

artículo científico publicado en 2011

Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.

artículo científico publicado en 2009

Mutations of the myeloid transcription factor CEBPA are not associated with the blast crisis of chronic myeloid leukaemia.

artículo científico publicado en 2006

Myelodysplastic Syndromes in Adolescent Young Adults: One Institution's Experience.

artículo científico publicado en 2016

Myelodysplastic syndromes

scientific article published on 01 August 1989

Myelodysplastic syndromes.

artículo científico publicado en 2004

Myelodysplastic syndromes: introduction

scientific article published on 01 February 1992

Naive T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency.

artículo científico publicado en 2012

New approaches to the treatment of myelodysplasia.

artículo científico publicado en 2002

New therapeutics for myelodysplastic syndromes.

artículo científico publicado en 2012

Non-Hodgkin's lymphoma of the gastrointestinal tract: an analysis of clinical and pathologic features affecting outcome ⬇️

artículo científico publicado el 1 de julio de 1988

Non-P-glycoprotein drug export mechanisms of multidrug resistance.

artículo científico publicado en 1997

Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies

artículo científico publicado en 2010

Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858

artículo científico publicado en 2017

On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia.

artículo científico publicado en 2008

Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes.

artículo científico publicado en 2003

Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models.

artículo científico

Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium

artículo científico publicado en 2014

Outcome of patients with myelodysplastic syndromes in the Veterans Administration population.

artículo científico publicado en 2009

Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome.

artículo científico publicado en 2010

Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents

scientific article published on 22 December 2015

PP2A: The Achilles Heal in MDS with 5q Deletion

artículo científico publicado en 2014

Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation.

artículo científico publicado en 2012

Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based survey

artículo científico publicado en 2011

Persistent malignant stem cells in del(5q) myelodysplasia in remission

artículo científico publicado en 2010

Pharmacological differentiation and anti-apoptotic therapy in myelodysplastic syndromes.

artículo científico publicado en 1999

Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome.

artículo científico publicado en 2009

Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome

artículo científico publicado en 2006

Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia

artículo científico publicado en 2019

Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.

artículo científico publicado en 2013

Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies

artículo científico publicado en 2013

Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia.

artículo científico publicado en 2001

Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia

artículo científico publicado en 1993

Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes.

artículo científico publicado en 2014

Poor Outcome of Patients With Myelodysplastic Syndrome After Azacitidine Treatment Failure

artículo científico publicado en 2013

Post-transplantation T-cell lymphoblastic lymphoma

scientific article published on 01 January 1988

Preclinical investigations of drug resistance

artículo científico publicado el 1 de enero de 1995

Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine

artículo científico publicado en 2013

Predominance of chromosome 5 deletions in myeloid neoplasia associated with solid tumors managed by surgical excision.

artículo científico publicado en 1992

Pretransplantation 5-azacitidine in high-risk myelodysplastic syndrome

artículo científico publicado en 2014

Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes

artículo científico publicado en 2007

Primary brain lymphoma in the immunocompetent host: relation to Epstein-Barr virus.

artículo científico publicado en 1990

Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group.

artículo científico publicado en 2000

Prognostic factors and risk models in myelodysplastic syndromes.

artículo científico publicado en 2013

Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies

artículo científico publicado en 2011

Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report

artículo científico publicado en 2015

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

artículo científico publicado en 2008

Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome.

artículo científico publicado en 2012

Ranitidine-induced granulocytopenia: recurrence with cimetidine administration

artículo científico publicado en 1988

Recurrent genetic defects on chromosome 5q in myeloid neoplasms.

artículo científico publicado en 2017

Recurrent hemorrhagic choroidal detachment associated with disseminated intravascular coagulation

scientific article published on 01 February 1992

Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromes.

artículo científico publicado en 2015

Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase

artículo científico publicado en 2010

Remitting activity of lenalidomide in treatment-induced myelodysplastic syndrome

scientific article published on 29 March 2007

Reply to Goel et al. 'TP53 mutation allele-burden and disease outcome in MDS/AML'

artículo científico publicado en 2016

Report of an unusual lymphoma arising from parafollicular B-lymphocytes (PBLs) or so-called "monocytoid" lymphocytes

artículo científico publicado en 1987

Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).

artículo científico publicado en 2018

Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulation.

artículo científico publicado en 2011

Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.

artículo científico publicado en 2017

Role of lenalidomide in the treatment of myelodysplastic syndromes.

artículo científico publicado en 2011

Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia.

artículo científico publicado en 1996

S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes

scientific article published on 08 February 2019

SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes.

artículo científico publicado en 2017

SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q

artículo científico publicado en 2018

STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients

artículo científico publicado en 2013

STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia

artículo científico publicado en 2012

SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia

artículo científico publicado en 2014

Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens.

artículo científico publicado en 2010

Selective exclusion by the polyamine transporter as a mechanism for differential radioprotection of amifostine derivatives.

artículo científico publicado en 2002

Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia

artículo científico publicado en 2009

Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study

artículo científico publicado en 2012

Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome.

artículo científico publicado en 2010

Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes

artículo científico publicado en 2016

Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial

artículo científico publicado en 2018

Spinal cord toxicity complicating treatment with cisplatin and etoposide

artículo científico publicado en 1990

Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT)

scientific article published on 07 January 2008

Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations

artículo científico publicado en 2012

Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome.

artículo científico publicado en 1997

Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.

artículo científico publicado en 2016

Suppressor of cytokine signaling-3 is overexpressed in erythroid precursors of myelodysplastic syndrome

scientific article published on 20 July 2006

T-cell large granular lymphocyte proliferation in myelodysplastic syndromes: Clinicopathological features and prognostic significance

artículo científico publicado en 2016

TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome

scientific article published on 16 June 2017

TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes.

artículo científico publicado en 2015

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

scientific article published on 11 January 2019

TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients

artículo científico publicado en 2013

Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression.

artículo científico publicado en 2015

Targeted therapies in myelodysplastic syndrome.

artículo científico publicado en 2008

Telomere length in myelodysplastic syndromes.

artículo científico publicado en 2011

The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype ⬇️

artículo científico publicado en 2016

The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval.

artículo científico publicado en 2017

The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes

scientific article published on 22 January 2019

The clinical management of chronic myelomonocytic leukemia

artículo científico publicado en 2014

The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update.

artículo científico publicado en 2008

The effects of delta9-tetrahydrocannabinol and cannabidiol on the metabolism of gonadal steroids in the rat ⬇️

artículo científico publicado el 1 de mayo de 1977

The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure

artículo científico publicado en 2016

The hematopoietic growth factors in the myelodysplastic syndromes.

artículo científico publicado en 2011

The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)

artículo científico publicado en 2018

The incidence of contrast medium induced acute tubular necrosis following arteriography

scientific article published on 01 January 1981

The myelodysplastic syndromes: biology and implications for management ⬇️

artículo científico publicado el 1 de agosto de 1990

The prognostic significance of IRF8 transcripts in adult patients with acute myeloid leukemia

artículo científico publicado en 2013

The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes

artículo científico publicado en 2017

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes

artículo científico publicado en 2015

The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications.

artículo científico publicado en 2016

The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer.

artículo científico publicado en 1986

Thrombosis associated with procainamide-induced lupus anticoagulant

scientific article published on 01 January 1989

Treatment of deletion 5q acute myeloid leukemia with lenalidomide

scientific article published on 18 January 2007

Tumor lysis syndrome complicating treatment of chronic lymphocytic leukemia with fludarabine phosphate

artículo científico publicado en 1990

Uncommon of the uncommon: low-grade myelodysplastic syndrome evolving into chronic myelogenous leukemia

scientific article published on 13 December 2010

Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype

artículo científico publicado en 2016

Update on the pharmacotherapy for myelodysplastic syndromes.

artículo científico publicado en 2014

Urine Galactomannan-to-Creatinine Ratio for Detection of Invasive Aspergillosis in Patients with Hematological Malignancies

artículo científico publicado en 2015

Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium

artículo científico publicado en 2020

Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q).

artículo científico publicado en 2014

Validation of the Lower-Risk MD Anderson Prognostic Scoring System for Patients With Myelodysplastic Syndrome.

artículo científico publicado en 2015

Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome.

artículo científico publicado en 2011

Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.

artículo científico publicado en 2013

Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes.

artículo científico publicado en 2001

WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides

artículo científico publicado en 2015

When clinical heterogeneity exceeds genetic heterogeneity: thinking outside the genomic box in chronic myelomonocytic leukemia.

artículo científico publicado en 2016

miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling

artículo científico publicado en 2013

Eficacia de la azacitidina en comparación con los regímenes de atención convencionales en el tratamiento de los síndromes mielodisplásicos de mayor riesgo: un estudio de fase III, aleatorizado, abierto

artículo científico publicado en 2009

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda